Dakshidin Corporation (DKSC), Signs LOI for Worldwide Exclusive Licensing Agreement

LAS VEGAS, Jan. 15, 2019 (GLOBE NEWSWIRE) — Dakshidin Corporation (DKSC) announced today that it had signed a Letter of Intent for a worldwide exclusive licensing agreement with GenBio, a biotechnology company based in Brisbane Australia. The agreement is for the exclusive rights to manufacture and distribute an entirely new product based on clinical research of a unique and proprietary superfood that GenBio has carried out over the last five years, infused with Dakshidin’s proprietary CBD formulas resulting in the only product of its kind on the market.

The focus of this new product will be to aid in arthritis pain relief, inflammation and early onset dementia (Alzheimer’s). Dakshidin CEO Chris Haigh stated: “This product will be a game changer not just for DKSC but in the industry. This industry is rife with products that make outlandish and unsupported claims about their effectiveness. We have a large body of verifiable science behind this product in addition to numerous studies performed by world-renowned scientists and research institutions. We hope to start trials later this month and release the product in Q2.”

More information to come after the licensing agreement has been signed.

As an additional update the company has finished the financials and is in the process of getting an opinion letter from an attorney which will be issued once the attorney’s due diligence is completed. Upon receipt of that letter the company will file with OTCmarkets and get current.

About Dakshidin Corporation (DKSC)
DKSC has positioned itself as an innovator in the emerging CBD and cannabis-derived products and services industry. The company is driven by three pillars of thought that guide the development of the business:

  1. Cannabis prohibition is approaching its inevitable end,
  2. Cannabis & CBD are conventional products used by a broad spectrum of consumers,
  3. Trusted brands will be the future of the cannabis industry.

About GenBio Inc.
Based in Brisbane Australia, GenBio is a pharmaceutical and nutraceutical research company that employs a proprietary drug discovery platform to generate novel therapeutic agents for use in multiple distinct indications. GenBio leads a team of International Scientists in developing new pharmaceutical products in the fields of pain relief, arthritis, asthma, and infectious diseases.

The company’s lead product under development, DEKOX(TM), is the first molecule in a new class of COX-2 selective / LOX-5 / LOX-15 triple inhibitors, protected with pending patents and owned exclusively.

The GenBio disruptive platform aims at the treatment of:

* Arthritis * Pain Relief * Inflammation * MRSA * Anti-Obesity * Anti-Aging Systems * Therapeutic * Irritable Bowel Syndrome * UTI * Asthma * Alzheimer’s


Forward-Looking Statements
The information in this press release includes certain “forward-looking” statements within the meaning of the Safe Harbor provisions of Federal Securities Laws. Investors are cautioned that such statements are based upon assumptions that in the future may prove not to have been accurate and are subject to significant risks and uncertainties, including the future financial performance of the Company. Although the Company believes that the expectations reflected in its forward-looking statements are reasonable, it can give no assurance that such expectations or any of its forward-looking statements will prove to be correct. Readers are cautioned not to place undue reliance on these forward-looking statements that speak only as of the date of this release, and the Company undertakes no obligation to update publicly any forward-looking statements to reflect new information, events, or circumstances after the date of this release except as required by law.

Dakshidin Corporation Investor Relations

Toll free: 1-800-986-6418
Martin Parr – Director

Email: dksc.corp@gmail.com
Twitter: https://twitter.com/whitechapelusa